Furthermore, recent major breakthroughs in the field of CKD treatment (particularly SGLT2 inhibitors and finerenone) and the improvement of SDI may cause the prediction of CKD disease burden to deviate from future reality, which increases the uncertainty of prediction. This evidence concerns the gene SLC5A2 and chronic kidney disease.